Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with high five year mortality which is partly due to the lack of therapeutic target specificity on common breast cancer receptors such as oestrogen receptor (ER), progesterone receptor (PR) or the human epidermal growth factor receptor 2 (HER2) [1]. Here, PGR is linked to breast cancer.